Company profile for Avenzo Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Avenzo Therapeutics, established in 2022 and co-founded by Dr. Athena Countouriotis and Dr. Mohammad Hirmand, is a clinical-stage biotechnology firm. Our primary focus is on developing and advancing a robust pipeline of oncology therapies with the aim of being among the best in their class. These therapies are designed to target cell cycle control mechanisms, with the goal of halting the abnormal proliferation of cells that is...
Avenzo Therapeutics, established in 2022 and co-founded by Dr. Athena Countouriotis and Dr. Mohammad Hirmand, is a clinical-stage biotechnology firm. Our primary focus is on developing and advancing a robust pipeline of oncology therapies with the aim of being among the best in their class. These therapies are designed to target cell cycle control mechanisms, with the goal of halting the abnormal proliferation of cells that is characteristic of many types of cancer. Our team boasts a proven track record within the industry for developing oncology treatments that hold promise in significantly impacting patients' lives for the better.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Suite 200, San Diego, CA 92130
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251211085624/en/Avenzo-Therapeutics-Presents-Initial-Results-from-the-Phase-12-Study-of-AVZO-021-a-Potential-Best-in-Class-CDK2-Inhibitor-at-the-2025-San-Antonio-Breast-Cancer-Symposium

BUSINESSWIRE
11 Dec 2025

https://www.businesswire.com/news/home/20251124173033/en/Avenzo-Therapeutics-Granted-Fast-Track-Designation-for-AVZO-103-a-Potential-Best-in-Class-Nectin4TROP2-Bispecific-Antibody-Drug-Conjugate-for-the-Treatment-of-Patients-with-Urothelial-Cancer-Previously-Treated-with-Enfortumab-Vedotin

BUSINESSWIRE
24 Nov 2025

https://www.businesswire.com/news/home/20251119935505/en/Avenzo-Therapeutics-Announces-Appointment-of-Scott-Lipman-as-Chief-Financial-Officer

BUSINESSWIRE
19 Nov 2025

https://www.businesswire.com/news/home/20251110260582/en/Avenzo-Therapeutics-Granted-Fast-Track-Designation-for-AVZO-1418-a-Potential-Best-in-Class-EGFRHER3-Bispecific-Antibody-Drug-Conjugate-for-the-Treatment-of-Patients-with-EGFR-Mutated-TKI-Pretreated-NSCLC

BUSINESS WIRE
10 Nov 2025

https://www.businesswire.com/news/home/20251030143206/en/Avenzo-Therapeutics-to-Present-Initial-Results-from-the-Phase-1-Study-of-AVZO-021-a-Potential-Best-in-Class-CDK2-Inhibitor-at-the-2025-San-Antonio-Breast-Cancer-Symposium

BUSINESSWIRE
30 Oct 2025

https://www.businesswire.com/news/home/20250929211412/en/Avenzo-Therapeutics-Initiates-Phase-12-Clinical-Study-of-AVZO-103-a-Potential-Best-in-Class-Nectin4TROP2-Bispecific-Antibody-Drug-Conjugate

BUSINESSWIRE
29 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty